Status:
ACTIVE_NOT_RECRUITING
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
SBRT
Radical Prostatectomy
Eligibility:
MALE
Phase:
NA
Brief Summary
Radical prostatectomy is a common treatment for localized prostate cancer. More than 30% of men who undergo surgery will subsequently develop recurrence, particularly in patients with adverse features...
Eligibility Criteria
Inclusion
- • Histologically confirmed diagnosis of adenocarcinoma of the prostate
- Completed written informed consent
- Able and willing to complete self report questionnaires
- Pathologic stage T3 or T4 (without any gross residual disease), NX-0, M0, and/or +ve surgical margins, and/or a rising PSA post-radical prostatectomy on at least 2 consecutive measurements
Exclusion
- • Gross residual disease
- Histological or radiological node +ve (N1) or distant metastases (M1)
- Prior pelvic radiotherapy
- Contraindications to radical pelvic radiotherapy (e.g. connective tissue disease or inflammatory bowel disease)
- Hip prosthesis
Key Trial Info
Start Date :
November 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2030
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04067570
Start Date
November 7 2019
End Date
October 1 2030
Last Update
May 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5